Hershko, Chaim published the artcilePhenolic ethylenediamine derivatives: a study of orally effective iron chelators, Name: 2-((2-(Pyridin-2-yl)hydrazono)methyl)pyridine, the publication is Journal of Laboratory and Clinical Medicine (1984), 103(3), 337-46, database is CAplus and MEDLINE.
Of 35 potential iron chelators screened for in vivo activity in rats, a group of phenolic compounds with excellent chelating properties were identified. These included N,N‘-ethylene-bis(o-hydroxyphenylglycine) (EHPG) [1170-02-1], NN‘-Bis(o-hydroxybenzyl)-ethylenediamine diacetic acid (HBED) [303-38-8], and their resp. di-Me esters (dmEHPG [90044-13-6] and dmHBED [85120-52-1]. All 4 phenolic compounds produced a marked increase in the fecal excretion of hepatocellular radioiron. This amounted to 42% of total body radioactivity with dmEHPG, 58% with EHPG, 60% with HBED, and 80% with dmHBED after a single injection of 40 mg/animal. At a dose of 5 mg/animal, EHPG, HBED, and dmHBED were 9, 12, and 15 times more potent, resp., than deferoxamine. Both di-Me esters showed significant oral activity: oral dmEHPG retained 1/3 and dmHBED retained 2/3 of the effect of the same dose given by i.m. injection. The ester dmHBED combines oral effectiveness with superior chelating ability, selective hepatocellular action, and low apparent toxicity. It may represent a significant advance in the development of new iron-chelating drugs.
Journal of Laboratory and Clinical Medicine published new progress about 2215-33-0. 2215-33-0 belongs to pyridine-derivatives, auxiliary class Pyridine,Amine, name is 2-((2-(Pyridin-2-yl)hydrazono)methyl)pyridine, and the molecular formula is C11H10N4, Name: 2-((2-(Pyridin-2-yl)hydrazono)methyl)pyridine.
Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem